Stanley Frankel insider trades: Precision Biosciences (DTIL) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Stanley reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | DTIL | ↑ Buy | 1,000 | $6.00 | $6K | Direct | Sep 30, 2026 (2d) |
| Dec 16, 2025 | DTIL | ↑ Buy | 2,700 | $4.70 | $13K | Direct | Dec 17, 2025 (1d) |
| Sep 26, 2025 | DTIL | ↑ Buy | 2,700 | $4.97 | $13K | Direct | Sep 30, 2025 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other DTIL insiders
Open-market trades in the last 12 months
About Stanley Frankel's insider trades
Stanley Frankel is a director at Precision Biosciences (DTIL). Since Sep 26, 2025, Stanley has reported 3 open-market purchases worth $32K and no sales on SEC Form 4. In the last 12 months: 2 buys ($19K).
Their filings also include grants and awards (5 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DTIL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.